A. M. Razmy, Ahamed Lebbe Failur Rahman, E. Lazarus, Thuvan Raheem Rajab, Mohamed Meerasahib Maroozathul Ilahi
{"title":"Risk of COVID-19 among patients with respiratory illnesses and comorbidities at Eastern Province of Sri Lanka: A retrospective study","authors":"A. M. Razmy, Ahamed Lebbe Failur Rahman, E. Lazarus, Thuvan Raheem Rajab, Mohamed Meerasahib Maroozathul Ilahi","doi":"10.4103/ijnpnd.ijnpnd_73_23","DOIUrl":null,"url":null,"abstract":"\n Background: There is a general belief that patients with comorbidities have a higher risk of contracting coronavirus disease 2019 (COVID-19) and subsequent death. However, there are significant gaps in understanding these risks. Objective: The study aimed to assess the risk of COVID-19 among respiratory illness patients admitted to the hospital with comorbidities. Method: A retrospective cohort study was conducted in a hospital in Sri Lanka, where the records of 428 patients with respiratory illness were studied for COVID-19 infection and comorbidities from 2020 to 2022. Results: In this sample, 67.1% had been infected with COVID-19 and 51.6% had comorbidities. The age group ≥60 years had two times higher risk for comorbidities, and the most frequently occurring condition was hypertension (58.8%). Surprisingly, the infection rate of COVID-19 among patients with comorbidities was 28% lower compared to patients with no comorbidities, but the odds ratio (OR) for dying was greater once the patient with comorbidities was infected with COVID-19 (OR = 7.5). An increased risk of death was observed for COVID-19 patients with diabetes mellitus (OR = 2), hypertension (OR = 2.5), heart diseases (OR = 4.3), and renal diseases (OR = 2.4). Conclusion: It was surprising to find that the infection rate and risk of death due to COVID-19 were lower among patients with chronic lung diseases. This could be due to early death at the beginning of the COVID-19 pandemic, less hospital admissions for patients with chronic lung diseases, or resistance to COVID-19, and these are factors that require further exploration.","PeriodicalId":14233,"journal":{"name":"International Journal of Nutrition, Pharmacology, Neurological Diseases","volume":"152 5-6","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Nutrition, Pharmacology, Neurological Diseases","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/ijnpnd.ijnpnd_73_23","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
Background: There is a general belief that patients with comorbidities have a higher risk of contracting coronavirus disease 2019 (COVID-19) and subsequent death. However, there are significant gaps in understanding these risks. Objective: The study aimed to assess the risk of COVID-19 among respiratory illness patients admitted to the hospital with comorbidities. Method: A retrospective cohort study was conducted in a hospital in Sri Lanka, where the records of 428 patients with respiratory illness were studied for COVID-19 infection and comorbidities from 2020 to 2022. Results: In this sample, 67.1% had been infected with COVID-19 and 51.6% had comorbidities. The age group ≥60 years had two times higher risk for comorbidities, and the most frequently occurring condition was hypertension (58.8%). Surprisingly, the infection rate of COVID-19 among patients with comorbidities was 28% lower compared to patients with no comorbidities, but the odds ratio (OR) for dying was greater once the patient with comorbidities was infected with COVID-19 (OR = 7.5). An increased risk of death was observed for COVID-19 patients with diabetes mellitus (OR = 2), hypertension (OR = 2.5), heart diseases (OR = 4.3), and renal diseases (OR = 2.4). Conclusion: It was surprising to find that the infection rate and risk of death due to COVID-19 were lower among patients with chronic lung diseases. This could be due to early death at the beginning of the COVID-19 pandemic, less hospital admissions for patients with chronic lung diseases, or resistance to COVID-19, and these are factors that require further exploration.
期刊介绍:
The International Journal of Nutrition, Pharmacology, Neurological Diseases (IJNPND) is an international, open access, peer reviewed journal which covers all fields related to nutrition, pharmacology, neurological diseases. IJNPND was started by Dr. Mohamed Essa based on his personal interest in Science in 2009. This journal doesn’t link with any society or any association. The co-editor-in chiefs of IJNPND (Prof. Gilles J. Guillemin, Dr. Abdur Rahman and Prof. Ross grant) and editorial board members are well known figures in the fields of Nutrition, pharmacology, and neuroscience. First, the journal was started as two issues per year, then it was changed into 3 issues per year and since 2013, it publishes 4 issues per year till now. This shows the slow and steady growth of this journal. To support the reviewers and editorial board members, IJNPND offers awards to the people who does more reviews within one year. The International Journal of Nutrition, Pharmacology, Neurological Diseases (IJNPND) is published Quarterly. IJNPND has three main sections, such as nutrition, pharmacology, and neurological diseases. IJNPND publishes Research Papers, Review Articles, Commentaries, case reports, brief communications and Correspondence in all three sections. Reviews and Commentaries are normally commissioned by the journal, but consideration will be given to unsolicited contributions. International Journal of Nutrition, Pharmacology, Neurological Diseases is included in the UGC-India Approved list of journals.